Talwalker S, Overall J E, Srirama M K, Gracon S I
Parke-Davis, Research Division, Warner Lambert Co., Ann Arbor, Michigan 48105, USA.
J Geriatr Psychiatry Neurol. 1996 Jan;9(1):39-46. doi: 10.1177/089198879600900107.
Factor analysis methodology applied to Alzheimer's Disease Assessment Scale (ADAS) subtest profiles for patients in two large-scale clinical trials of the antidementia drug tacrine yielded three oblique factors interpreted as dysfunctions in memory, language, and praxis. The factor structures confirmed reliable assessment of primary dimensions of cognitive impairment in Alzheimer's disease that the original authors of the ADAS proposed to measure and that correspond well to that of the only previously reported factor analysis of the ADAS-COG. The presence of a strong general factor, supported by stable correlations among the oblique primary factors, justifies the recommendation to continue reliance on the ADAS-COG total score as a primary outcome measure in clinical trials, whereas the factor scores are recommended for evaluation of differential treatment effects on more specific aspects of the general cognitive decline. The stability of correlations across time appears to satisfy a primary requirement for application of repeated measures ANOVA to ADAS-COG total score and factor scores in longitudinal clinical trials.
在两项针对抗痴呆药物他克林的大规模临床试验中，将因子分析方法应用于阿尔茨海默病评估量表（ADAS）子测试剖面图，得出了三个斜交因子，分别解释为记忆、语言和实践功能障碍。这些因子结构证实了对阿尔茨海默病认知障碍主要维度的可靠评估，ADAS的原作者提议测量这些维度，且这些维度与之前唯一报道的ADAS-COG因子分析结果非常吻合。存在一个强大的一般因子，得到斜交主要因子之间稳定相关性的支持，这证明了在临床试验中继续依赖ADAS-COG总分作为主要结局指标的建议是合理的，而推荐使用因子得分来评估对一般认知衰退更具体方面的差异治疗效果。跨时间相关性的稳定性似乎满足了在纵向临床试验中将重复测量方差分析应用于ADAS-COG总分和因子得分的主要要求。
